Skip to main content
. 2014 Jun 23;20(2):140–147. doi: 10.1017/S1092852914000285

Figure 3a.

Figure 3a

Proportion of patients who were depressive symptom responders at endpoint (last observation carried forward), by severity of depressive symptoms at baseline. (Depressive symptom responders are defined as those with a ≥50% decrease from baseline in Montgomery–Åsberg Depression Rating Scale [MADRS] score.) P values for comparisons of lurasidone (dose groups pooled) versus placebo were not significant. NNT: number needed to treat.